Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised

4.8 (643) · € 17.00 · En Stock

Docetaxel plus cetuximab biweekly is an active regimen for the

Biomedicines, Free Full-Text

Safety and preliminary activity of pembrolizumab‑carboplatin

Durvalumab with or without tremelimumab versus the EXTREME regimen

PDF] Pembrolizumab alone or with chemotherapy versus cetuximab

First‐line cetuximab + platinum‐based therapy for recurrent

Weekly paclitaxel, carboplatin and cetuximab (PCE) combination

Targeted therapy for head and neck cancer: signaling pathways and

A pilot study of camrelizumab with docetaxel and cisplatin for the